Neuphoria Therapeutics Inc.
NEUP
$4.73
-$0.11-2.27%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -141.46% | 69.27% | 4.24% | 39.94% | 16.78% |
| Total Depreciation and Amortization | 0.24% | -50.02% | 0.00% | 100.06% | -0.12% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 51.73% | -157.63% | -0.80% | -252.37% | 81.79% |
| Change in Net Operating Assets | 72.62% | -264.78% | 0.00% | 442.63% | -141.14% |
| Cash from Operations | 24.25% | -72.65% | 4.03% | 32.18% | 10.94% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -2.30% | -- | -- |
| Cash from Investing | -- | -- | -2.30% | -- | -- |
| Total Debt Issued | -- | -- | -2.31% | -- | -- |
| Total Debt Repaid | -- | -- | 2.54% | -- | -- |
| Issuance of Common Stock | -- | -99.97% | -5.58% | 413.61% | -95.39% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 51.16% | -108.10% | 0.25% | -47.47% | 194.49% |
| Cash from Financing | 50.90% | -105.89% | -2.12% | -29.92% | 818.58% |
| Foreign Exchange rate Adjustments | -299.93% | -14.20% | 1.77% | -53.82% | 324.61% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 17.15% | -427.35% | 1.88% | -33.02% | 150.99% |
